Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-12-14
1997-07-08
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 15, 514 16, 530327, 530328, 530329, A61K 3808, C07K 500
Patent
active
056461208
ABSTRACT:
Described herein are oligopeptides useful to inhibit replication in virally infected individuals. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 5 uM concentration, exhibits greater than 95% inhibition of HIV replication, in a standard assay.
REFERENCES:
patent: 4042330 (1977-08-01), Deshmukh
patent: 4252784 (1981-02-01), Levine
patent: 4447356 (1984-05-01), Olivena
patent: 4713366 (1987-12-01), Stevens
patent: 5093317 (1992-03-01), Lewis
patent: 5110802 (1992-05-01), Cantin et al.
patent: 5135736 (1992-08-01), Anderson et al.
patent: 5171838 (1992-12-01), Chiba
Spatola,"Peptide Bond Modifications . . . " Chemistry and Biochemistry of Amino Acids, Peptides & Proetins (Weinstein 1983) 267-357.
Ruben et al. (1989) J. Vir. 63(1): 1-8.
Weeks et al. Science vol. 249, 1281-85 (Sep. 1990).
Stryer (1981) Biochemistry 2: 123-127.
Ratner et al. (1985) Nature 313:277, "Complete nucleotide sequence of the AIDS virus, HTLV-III".
Kuppuswamy et al. (1989) Nucleic Acids Research 17(9): 3551, "Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis".
Hauber et al., (1989) J. Virol. 63(3):1811, "Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein".
Green et al. (1989) Cell 58:215, "Mutational analysis of HIV-1 tat minimal domain peptides: identification of trans-dominant mutants that supress HIV-LTR-Driven gene expression".
Weeks et al. (1990) Science 249:1281, "Fragments of the HIV-I tat protein specifically bind TAR RNA".
Ruben et al. (1989) J. Virol. 63(1):1, "Structural and functional charaterization of human immunodeficiency virus tat protein".
Roy et al. (1990) Genes and Development 4:1365, "A bulge structure in HIV-I TAR RNA is required for tat binding and tat-mediated trans-activation".
Green et al. (1988) Cell 55:1179, "Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein".
Frankel et al. (1989) Proc. Nat'l. Acad. Science 86:7397, "Activity of synthetic peptides from the tat protein of human immunodeficiency virus type 1".
Stryer, (1981) Biochemistry 2:123-127, "Electrostatic, hydrogen, and Van Der Waals bonds in enzyme-substrate complexes".
ASM News, vol. 56 No. 7 (Jul. 1990) at 368.
Docherty Antimicrob Agents Chemother 31, 1562, 1987.
Coy, Biochem Biophys Res Comm 73, 632, 1976.
Burger J Biol Chem 193, 13, 1951.
Choppin et al. "Analysis of Physical Interactions between Peptides and HLA Molecules and Application to the Detection . . . ", J. Exp. Med., 172:889-899, 1990.
Arnold, Jr., "Polylysin-Drug Conjugates," Methods in Enzymology, vol. 112, pp. 270-285 (1985).
Barnett Richard W.
Reid Lorne S.
Sonenberg Nahum
Sumner-Smith Martin
Allelix Biopharmaceuticals Inc.
Lukton David
Tsang Cecilia J.
LandOfFree
Peptide-based inhibitors of HIV replication does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide-based inhibitors of HIV replication, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide-based inhibitors of HIV replication will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2408873